Dividend Center Best Dividend Stocks

Best High Yield Dividend Stocks Dividend Aristocrats Dividend Stock Comparison

Dividend Calculator Dividend Returns Comparison Dividend Calendar

My Experts Top Analysts Top Financial Bloggers Top-Performing Corporate Insiders Top Hedge Fund Managers Top Research Firms Top Individual Investors

Personal Finance Center Mortgages Loans Investing & Retirement Spending & Savings

Calculators

401k Retirement Calculator Mortgage Calculator

Compound Interest Calculator Dollar Cost Averaging

Student Loan Calculator Auto Loan Calculator

Education

How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

Follow Us

News Trending Portfolio

TOOLS

Top Insiders Stocks

Top Smart Score Stocks

STOCKS

Dividend Center

Best Dividend Stocks

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

Personal Finance Center

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Mortgage Calculator

Auto Loan Calculator

Student Loan Calculator

401k Retirement Calculator

Enterprise Solutions

Plans & Pricing

Education

How To Use TipRanks

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

Follow Us

Hikma Pharmaceuticals PLC (GB:HIK)

LSE:HIK

HIK

Hikma Pharmaceuticals

Analyst Forecasts

Technical Analysis

RESEARCH TOOLS

Top Analyst Stocks

Top Smart Score Stocks

reports

Hikma Pharmaceuticals (HIK) Share Forecast & Price Target

31 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HIK Analyst Ratings

Moderate Buy

2 Buy

4 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Hikma

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HIK Stock 12 Month Forecast

Average Price Target

2,270.83p

▲(23.41% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is 2,270.83p with a high forecast of 2,750.00p and a low forecast of 2,000.00p. The average price target represents a 23.41% change from the last price of 1,840.00p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1723":"1,723p","1980":"1,980p","2237":"2,237p","2494":"2,494p","2751":"2,751p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2750,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">2.75K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2270.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">2.27K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2000,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">2.00K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1723,1980,2237,2494,2751],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"Jun<br/>2024","25":"Jun<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1949,2010.6153846153845,2072.230769230769,2133.846153846154,2195.4615384615386,2257.076923076923,2318.6923076923076,2380.3076923076924,2441.923076923077,2503.5384615384614,2565.153846153846,2626.7692307692305,2688.3846153846152,{"y":2750,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1949,1973.756153846154,1998.5123076923078,2023.2684615384615,2048.0246153846156,2072.7807692307692,2097.536923076923,2122.293076923077,2147.0492307692307,2171.8053846153844,2196.5615384615385,2221.317692307692,2246.0738461538463,{"y":2270.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1949,1952.923076923077,1956.8461538461538,1960.7692307692307,1964.6923076923076,1968.6153846153845,1972.5384615384614,1976.4615384615386,1980.3846153846155,1984.3076923076924,1988.2307692307693,1992.1538461538462,1996.076923076923,{"y":2000,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1837.98,"date":1688083200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1795.69,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2041.66,"date":1691107200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2131.61,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2035.48,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1770.13,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1724.52,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1823.59,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1841.25,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1896.67,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1863,"date":1712275200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1960,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1949,"date":1717718400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target2,750p

Average Price Target2,271p

Lowest Price Target2,000p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Barclays

Reiterated

06/26/24

xxxxxxxxxxxxxxxxxx

Deutsche Numis

Reiterated

06/18/24

xxxxxxxxxxxxxxxxxx

Stifel Nicolaus

Stifel Nicolaus

Reiterated

06/17/24

xxxxxxxxxxxxxxxxxx

RBC Capital

Reiterated

04/29/24

xxxxxxxxxxxxxxxxxx

Berenberg Bank

Reiterated

04/26/24

xxxxxxxxxxxxxxxxxx

CFRA

Reiterated

04/26/24

Thibault Boutherin

Morgan Stanley

1,900p→2,000p

Hold

8.70%

Upside

Reiterated

03/19/24

Hikma Pharmaceuticals Plc (HIK:LN) (HKMPF) PT Raised to GBP20 at Morgan StanleyMorgan Stanley analyst Thibault Boutherin raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP20.00 (from GBP19.00) while maintaining a Equalweight rating.

J.P. Morgan Analyst forecast on GB:HIK

J.P. Morgan

22p→2,350p

Buy

27.72%

Upside

Reiterated

02/23/24

Hikma Pharmaceuticals Plc (HIK:LN) (HKMPF) PT Raised to GBP23.50 at JPMorganJPMorgan analyst James Gordon raised the price target on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) to GBP23.50 (from GBP22.00) while maintaining a Overweight rating.

Jefferies Analyst forecast on GB:HIK

Jefferies

1,880p

Hold

2.17%

Upside

Reiterated

12/21/23

Citi Analyst forecast on GB:HIK

Citi

2,630p

Buy

42.93%

Upside

Reiterated

12/04/23

Best Analysts Covering Hikma Pharmaceuticals

Which Analyst Should I Follow If I Want to Buy GB:HIK and Sell After:

1 Month

Peter VerdultCiti

Success Rate

7/14 ratings generated profit

Average Return

+2.52%

reiterated a buy rating 7 months ago

Copying Peter Verdult's trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +2.52% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

3 Months

Peter VerdultCiti

Success Rate

11/14 ratings generated profit

Average Return

+8.47%

reiterated a buy rating 7 months ago

Copying Peter Verdult's trades and holding each position for 3 Months would result in 78.57% of your transactions generating a profit, with an average return of +8.47% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

1 Year

Peter VerdultCiti

Success Rate

11/14 ratings generated profit

Average Return

+7.21%

reiterated a buy rating 7 months ago

Copying Peter Verdult's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +7.21% per trade.

2 Years

Peter VerdultCiti

Success Rate

8/14 ratings generated profit

Average Return

-6.48%

reiterated a buy rating 7 months ago

Copying Peter Verdult's trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of -6.48% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HIK Analyst Recommendation Trends

Rating

Feb 24

Mar 24

Apr 24

May 24

Jun 24

Strong Buy

0

0

0

0

0

Buy

3

1

1

1

3

Hold

9

8

9

6

6

Sell

0

0

0

0

0

Strong Sell

0

0

0

0

0

total

12

9

10

7

9

In the current month, HIK has received 3 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. HIK average Analyst price target in the past 3 months is 2,270.83p.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

HIK Financial Forecast

HIK Earnings Forecast

The previous quarter’s earnings for HIK were 0.21p.

The previous quarter’s earnings for HIK were 0.21p.

HIK Sales Forecast

Next quarter’s sales forecast for HIK is 1.19B with a range of 1.19B to 1.19B. The previous quarter’s sales results were 1.16B. HIK beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 45.45% of the time in the same period. In the last calendar year HIK has Outperformed its overall industry.

Next quarter’s sales forecast for HIK is 1.19B with a range of 1.19B to 1.19B. The previous quarter’s sales results were 1.16B. HIK beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 45.45% of the time in the same period. In the last calendar year HIK has Outperformed its overall industry.

HIK Stock Forecast FAQ

What is GB:HIK’s average 12-month price target, according to analysts?

Based on analyst ratings, Hikma Pharmaceuticals PLC’s 12-month average price target is 2,270.83p.

What is GB:HIK’s upside potential, based on the analysts’ average price target?

Hikma Pharmaceuticals PLC has 23.41% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Hikma Pharmaceuticals PLC a Buy, Sell or Hold?

Hikma Pharmaceuticals PLC has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 4 hold ratings and 0 sell ratings.

What is Hikma Pharmaceuticals PLC’s share price target?

The average share price target for Hikma Pharmaceuticals PLC is 2,270.83p. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 2,750.00p ,and the lowest forecast is 2,000.00p. The average share price target represents 23.41% Increase from the current price of 1,840p.

What do analysts say about Hikma Pharmaceuticals PLC?

Hikma Pharmaceuticals PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of Hikma Pharmaceuticals PLC?

To buy shares of GB:HIK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing